Sentinel lymph node biopsy or detection of micrometastasis in bone marrow: Which might be an alternative to axillary lymph node dissection in breast cancer patients?

Asian Journal of Surgery

Volumn 27, Issue 4, 2004, Pages 279-283

  Zhu, Li ^a   Lam, Chi Kei ^a   Chow, Louis W C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKERATIN; EOSIN; HEMATOXYLIN;

AXILLARY LYMPH NODE; BONE MARROW METASTASIS; BONE MARROW MICROMETASTASIS; BREAST CANCER; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; METASTASIS; PROGNOSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TISSUE SECTION;

EID: 7044269110     PISSN: 10159584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1015-9584(09)60051-8     Document Type: Conference Paper

References (51)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:1811-87.
2. Chambers AF, Naumov GN, Vantyghem SA, et al. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res 2000;2:400-7.
3. Harris MN, Shapiro RL, Roses DF. Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer 1995;75(2 Suppl):715-25.
4. Cabanas RM. An approach for the treatment of penile cancer. Cancer 1977;39:456-61.
5. Krag DN, Weaven DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9.
6. Albertini J, Cox C, Yeatman T, et al. Lymphatic mapping and sentinel node biopsy in the breast cancer patient. Proc Am Soc Clin Oncol 1995;14:A99. (Abstract)
7. Statman RD, Jones RC, Cabot MC, et al. Sentinel lymphadenectomy. A technique to eliminate axillary dissection in node-negative breast cancer. Proc Am Soc Clin Oncol 1996;15:A167. (Abstract)
8. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
9. Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998;5:126-30.
10. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
11. Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720-6.
12. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-6.
13. Foulds L. The experimental study of tumor progression: a review. Cancer Res 1954;14:327-39.
14. Jendraschak E, Sage EH. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 1996;7:139-46.
15. Hermanek P, Hutter RV, Sobin LH, et al. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999;86:2668-73.
16. th edition. Philadelphia: Lippincott-Raven, 1997:171-80.
17. th edition. Geneva: Wiley-Liss, 2002:131-41.
18. Tjan-Heijnen VC, Bult P, de Widt-Lever LM, et al. Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 2001;70:81-8.
19. Page DL, Anderson TJ, Carter BA. Minimal solid tumor involvement of regional and distant sites: when is a metastasis not a metastasis? Cancer 1999;86:2589-92.
20. Weaver DL. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards. Adv Anat Pathol 2001;8:65-73.
21. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. A preliminary study. Cancer 1999;86:990-6.
22. Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-8.
23. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-401.
24. Turner RR, Ollila DW, Stern S, et al. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 1999;23:263-7.
25. Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999;85:1098-103.
26. Schreiber RH, Pendas S, Ku NN, et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 1999;6:95-101.
27. Liu LH, Siziopikou KP, Gabram S, et al. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med 2000;124:1670-3.
28. Bostick PJ, Huynh KT, Sarantou T, et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 1998;79:645-51.
29. Meyer JS. Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. J Surg Oncol 1998;69:212-8.
30. Edwards M, Martin KD, McMasters KM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Surg Oncol 1998;7:51-7.
31. Singh Ranger G, Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol 2003;29:423-5.
32. Roberts A, Cochran AJ. Current management of sentinel lymph nodes: perspectives from pathology. Curr Diagn Pathol 2003;9:199-210.
33. Brady M, Thayer D. Sentinel lymph node biopsy for melanoma: review of published experience. In: Cody HSC III, ed. Sentinel Lymph Node Biopsy. New York: Martin Dunitz, 2002:161-73.
34. Morton D, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63.
35. McMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol 2001;8(9 Suppl):41S-3S.
36. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
37. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
38. Yoshihisa U, Yasuyo O, Yoshiatsu S, et al. Clinical significance of occult micrometastases in axillary lymph nodes in "node-negative" breast cancer patients. Jpn J Cancer Res 2002;93:695-8.
39. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553-9.
40. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, et al. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001;77:165-70.
41. Noguchi M. Sentinel lymph node biopsy in breast cancer: an overview of the Japanese experience. Breast Cancer 2001;8:184-94.
42. Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000;88:1099-107.
43. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer, prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
44. Mansi JL, Gogas H, Bliss JM, et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354:197-202.
45. Carter BA, Jensen RA, Simpson JF, et al. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000;113:259-65.
46. Page DL, Carter BA. Sentinel lymph nodes, breast cancer, and pseudometastasis. Breast Dis: A Year Book Quarterly 2002;12:362-3.
47. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. NEngl J Med 2000;342:525-33.
48. Gebauer G, Fehm T, Merkle E, et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001;19:3669-74.
49. Fisher B, Fisher ER, Guzman C, et al. The dissemination of subcutaneously inoculated tumor cell suspensions. Arch Surg 1968;98:347-51.
50. Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001;19:1468-75.
51. Woelfle U, Cloos J, Riethdorf L, et al. A new role of cytokeratins as micrometastasis-suppressors in primary breast cancer. Proc Am Assoc Cancer Res 2003,44:118.